PRN Archives - Page 4 of 8

Developments

Profound Medical gets recommendation from Timelo Investment

During a BNN Bloomberg TV interview, Jean-Francois Tardif, founder and portfolio manager of Timelo Investment Management, praised the prospects of Profound Medical (NASDAQ:PROF; TSX:PRN). “Profound has an FDA-approved...

September 20, 2021

Developments

Raymond James study finds superior safety and TAM with Profound Medical’s TULSA-PRO

Raymond James gave winning marks to Profound Medical‘s (NASDAQ:PROF; TSX:PRN) TULSA-PRO device, compared with the Focal One HIFU device from France’s EDAP TMS SA (NASDAQ:EDAP), in a head-to-head comparison study...

August 26, 2021

Developments

Profound Medical posts sequential 145% jump in Q2 recurring revenue

Profound Medical (NASDAQ:PROF; TSX:PRN) reported a 145% increase in recurring revenue for the second quarter, compared with the first quarter of 2021. Total revenue, including capital sales outside of the U.S...

August 5, 2021

Developments

Profound’s TULSA-PRO posts better safety, equal efficacy in real-world analysis of prostate cancer partial ablation, BPH

A peer-reviewed paper authored by clinicians and researchers from Germany’s ALTA Klinik and the University Hospital, LMU Munich, and published in Urologic Oncology illustrates that Profound Medical’s...

June 21, 2021

Developments

Profound Medical, Akumin in U.S. multi-center commercial pact for TULSA-PRO

Profound Medical (NASDAQ:PROF; TSX:PRN) signed a multi-site imaging center agreement for its TULSA-PRO device with Akumin (NASDAQ, TSX:AKU), a leading provider of freestanding, fixed-site outpatient diagnostic imaging...

May 6, 2021

Developments

Profound Medical Q4 preliminary revenue beats consensus estimates

Profound Medical (NASDAQ:PROF; TSX:PRN) preliminary revenue for the fourth quarter of 2020 of $3.7-million beat the Street estimate of $2.7-million, despite the pandemic surge. “We believe strong TULSA-PRO adoption and...

January 6, 2021

Markets

Leede Jones Gable starts Profound Medical at buy; PT $36.50 (Canadian)

Leede Jones Gable launched coverage of Profound Medical (TSX:PRN) with a “buy” rating and price target of $36.50 (Canadian). The stock gained $2.96, or 13%, to close at $26.18 on Dec. 21. The firm’s flagship device...

December 22, 2020

Developments

Profound Medical in pact with GE Healthcare to expand access to TULSA-PRO

Profound Medical (NASDAQ:PROF; TSX:PRN) and GE Healthcare agreed to a non-exclusive, worldwide license that will enable Profound to interface its TULSA-PRO system with certain GE Healthcare MRI scanners. The...

December 21, 2020

Developments

Profound Medical gets FDA humanitarian device exemption approval for Sonalleve

Profound Medical’s (NASDAQ:PROF; TSX:PRN) Sonalleve received FDA humanitarian device exemption (HDE) approval for the treatment of osteoid osteoma. Osteoid osteoma is a non-cancerous bone tumor that occurs most often in...

November 30, 2020

Executive Moves

Profound Medical appoints accomplished financial executive, Murielle Lortie, to board

Murielle Lortie Profound Medical (NASDAQ:PROF; TSX:PRN) appointed financial executive, Murielle Lortie, as a director, effective immediately. Ms. Lortie is the CFO of Liminal Biosciences, a Nasdaq-listed, clinical-stage...

November 30, 2020

Tag - PRN

Profound Medical gets recommendation from Timelo Investment

Raymond James study finds superior safety and TAM with Profound Medical’s TULSA-PRO

Profound Medical posts sequential 145% jump in Q2 recurring revenue

Profound’s TULSA-PRO posts better safety, equal efficacy in real-world analysis of prostate cancer partial ablation, BPH

Profound Medical, Akumin in U.S. multi-center commercial pact for TULSA-PRO

Profound Medical Q4 preliminary revenue beats consensus estimates

Leede Jones Gable starts Profound Medical at buy; PT $36.50 (Canadian)

Profound Medical in pact with GE Healthcare to expand access to TULSA-PRO

Profound Medical gets FDA humanitarian device exemption approval for Sonalleve

Profound Medical appoints accomplished financial executive, Murielle Lortie, to board

General

More